Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
Jennifer Alleva(United States Nuclear Regulatory Commission), Joel P. Bercu(Eli Lilly (United States)), Kate Arnot(AstraZeneca (United Kingdom)), Mayur S. Mitra(GenVec), Alejandra Trejo‐Martin(Gilead Sciences (United States)), Kaushik Datta(Bristol-Myers Squibb (Germany)), Elizabeth A. Martin(AstraZeneca (South Korea)), John Nicolette(AbbVie (United States)), Teresa C. Wegesser(Amgen (United States))
Cited by 0
Related Papers
Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2023|34
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32
Qualification of impurities based on metabolite data
|Regulatory Toxicology and Pharmacology|2019|20
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
|Regulatory Toxicology and Pharmacology|2023|15